Association of CYP2C19 Polymorphisms with Survival of Breast Cancer Patients Using Tamoxifen: Results of a Meta-analysis

Bai, Lan; He, Juan; He, Gong-Hao; He, Jian-Chang; Xu, Fan; Xu, Gui-Li

추천

검색

자료유형: 학술저널

저자정보: Bai, Lan (Department of Pharmacy, Kunming General Hospital of Chengdu Military Command) He, Juan (Department of Pharmacy, Kunming General Hospital of Chengdu Military Command) He, Gong-Hao (Department of Pharmacy, Kunming General Hospital of Chengdu Military Command) He, Jian-Chang (Department of Pharmacy, Kunming General Hospital of Chengdu Military Command) Xu, Fan (Department of Ophthalmology, People's Hospital of Guangxi Zhuang Autonomous Region) Xu, Gui-Li (Department of Pharmacy, Kunming General Hospital of Chengdu Military Command)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제19호

발행연도: 2014.1

수록면: 8,331 - 8,335 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Previous studies accessing the association of CYP2C19 with outcomes of patients using tamoxifen for breast cancer have yielded conflicting results. The aim of this meta-analysis is to obtain a more precise estimate of effects of CYP2C19 polymorphisms and to clarify their effects on survival of the breast cancer patients using tamoxifen. Materials and Methods: A systematic search of PubMed and Embase was performed, comparing patients with or without $CYP2C19^*2$ and $CYP2C19^*17$, relevant articles searched for. The following outcomes were included from the eligible studies: disease-free survival (DFS) and overall survival (OS), expressed by hazard ratios (HR) with corresponding 95% confidence interval (CI). Subgroup analysis by genotypes was also performed. Pooled estimates were calculated using random-effect model in accordance to the heterogeneity. Results: Six studies met the inclusion criteria. The integrated OR on the association between CYP2C19 and DFS, calculated by the random-effect model, was 0.54 (95%CI=0.34-0.84, p=0.013). Subgroup analysis showed that both $CYP2C19^*2$ and $CYP2C19^*17$ were associated with increased survival. The pooled results of two studies for OS were OR=0.46 (95%CI=0.21-1.01, p=0.233). Conclusions: This meta-analysis suggests that the $CYP2C19^*2$ and $CYP2C19^*17$ genotypes are associated with increased survival in breast cancer patients using tamoxifen.

#Breast cancer #$CYP2C19^*2$ #$CYP2C19^*17$ #survival #tamoxifen #meta-analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요